Prognosis of patients with suspected pulmonary embolism in Buenos Aires: a prospective cohort study

BMC Pulmonary Medicine

Diego Hernan Giunta²  Fernán González Bernaldo de Quirós²  María Lourdes Posadas-Martínez²  Fernando Javier Vazquez¹ 

[1] Department of Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;Research Area in Internal Medicine, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

关键词: Comorbidities;    Mortality;    Suspected pulmonary embolism;    Outcome;    Prognosis;    Pulmonary embolism;   

Others  :  1090813
DOI  :  10.1186/1471-2466-14-200

 received in 2014-05-26, accepted in 2014-12-11,  发布年份 2014

【 摘 要 】

Background

The prognosis of patients with suspected pulmonary embolism (PE) in whom PE has been ruled out (RPE) is unclear. We aimed to evaluate survival and diagnosis of new cancer in suspected PE patients at follow up.

Methods

A prospective cohort study nested in a prospective Institutional Registry of Venous Thromboembolic Disease was performed between 2006 and 2011. This study was designed to evaluate all consecutive, incident cases of suspected PE in adults. The study was performed at the Hospital Italiano de Buenos Aires, a tertiary level hospital, in hospitalized patients and outpatients. Suspected PE cases were collected using a computerized system that alerts whenever a physician requests pulmonary angiography, angiotomography, or ventilation-perfusion scintigraphy. PE was defined by pre-specified criteria and RPE was defined when diagnostic tests were negative for PE.

Results

We included 1736 cases of suspected PE. The prevalence of PE was 29% (n = 504). There was no difference in the overall survival at 30 days and follow-up between PE and RPE patients. The presence of provoked or unprovoked venous thromboembolic disease in these patients did not affect survival. The main causes of death were PE in the confirmed PE group (60%), and neoplasm (42%) and sepsis (37%) in the RPE group. Survival at 90 days was 63% for PE (95% CI 58–67%) and 67% for RPE patients (95% CT 64–69%). At follow-up, there was no difference in diagnosis of new cancer between PE and RPE patients (2% vs 2%, p = 0.82), even when taking into account the unprovoked group.

Conclusions

Even when the main cause of death in PE patients is PE itself, the overall mortality is similar between PE and RPE patients. The reason for this finding could be because of the more frequent and severe comorbidities in RPE than in PE patients.

Trial registration

HomeClinicalTrial.gov: NCT01372514

【 授权许可】

   
2014 Vazquez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW: Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(6 Suppl):381S-453S.
• [2]Girard P, Sanchez O, Leroyer C, Musset D, Meyer G, Stern JB, Parent F: Deep venous thrombosis in patients with acute pulmonary embolism: prevalence, risk factors, and clinical significance. Chest 2005, 128(3):1593-1600.
• [3]Lobo JL, Zorrilla V, Aizpuru F, Uresandi F, Garcia-Bragado F, Conget F, Monreal M: Clinical syndromes and clinical outcome in patients with pulmonary embolism: findings from the RIETE registry. Chest 2006, 130(6):1817-1822.
• [4]Laporte S, Mismetti P, Decousus H, Uresandi F, Otero R, Lobo JL, Monreal M: Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 2008, 117(13):1711-1716.
• [5]Wells PS, Ginsberg JS, Anderson DR, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J: Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998, 129(12):997-1005.
• [6]Le Gal G, Righini M: Pulmonary embolism in patients with unexplained exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006, 145(4):310. author reply 310
• [7]Le Gal G, Righini M, Roy PM, Sanchez O, Aujesky D, Bounameaux H, Perrier A: Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006, 144(3):165-171.
• [8]Baglin TP, White K, Charles A: Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997, 50(7):609-610.
• [9]Righini M, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Rutschmann O, Nonent M, Cornuz J, Thys F, Le Manach CP, Revel MP, Polletti PA, Meyer G, Mottier D, Perneger T, Bounameaux H, Perrier A: Diagnosis of pulmonary embolism by multidetector CT alone or combined with venous ultrasonography of the leg: a randomised non-inferiority trial. Lancet 2008, 371(9621):1343-1352.
• [10]The PIOPED, Investigators: Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990, 263(20):2753-2759.
• [11]Worsley DF, Alavi A: Comprehensive analysis of the results of the PIOPED Study. Prospective Investigation of Pulmonary Embolism Diagnosis Study. J Nucl Med 1995, 36(12):2380-2387.
• [12]van Beek EJ, Tiel-van Buul MM, Buller HR, van Royen EA, ten Cate JW: The value of lung scintigraphy in the diagnosis of pulmonary embolism. Eur J Nucl Med 1993, 20(2):173-181.
• [13]Akram AR, Cowell GW, Logan LJ, Macdougall M, Reid JH, Murchison JT, Simpson AJ: Clinically suspected acute pulmonary embolism: a comparison of presentation, radiological features and outcome in patients with and without PE. QJM 2009, 102(6):407-414.
• [14]Forauer AR, McLean GK, Wallace LP: Clinical follow-up of patients after a negative digital subtraction pulmonary arteriogram in the evaluation of pulmonary embolism. J Vasc Interv Radiol 1998, 9(6):903-908.
• [15]van Strijen MJ, Bloem JL, de Monye W, Kieft GJ, Pattynama PM, van den Berg-Huijsmans A, Huisman MV, Antelope-Study G: Helical computed tomography and alternative diagnosis in patients with excluded pulmonary embolism. J Thromb Haemost: JTH 2005, 3(11):2449-2456.
• [16]Poulsen SH, Noer I, Moller JE, Knudsen TE, Frandsen JL: Clinical outcome of patients with suspected pulmonary embolism. A follow-up study of 588 consecutive patients. J Intern Med 2001, 250(2):137-143.
• [17]Carson JL, Kelley MA, Duff A, Weg JG, Fulkerson WJ, Palevsky HI, Schwartz JS, Thompson BT, Popovich J Jr, Hobbins TE, Spera MA, Alavi A, Terrin ML: The clinical course of pulmonary embolism. N Engl J Med 1992, 326(19):1240-1245.
• [18]Roy PM, Meyer G, Vielle B, Le Gall C, Verschuren F, Carpentier F, Leveau P, Furber A: Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med 2006, 144(3):157-164.
• [19]Goldhaber SZ, Visani L, De Rosa M: Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999, 353(9162):1386-1389.
• [20]Kucher N, Rossi E, De Rosa M, Goldhaber SZ: Massive pulmonary embolism. Circulation 2006, 113(4):577-582.
• [21]Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM: Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007, 98(4):756-764.
• [22]Mazzei JA, Campos AL, Melero MJ: Frequency and incidence of venous thromboembolism in a general hospital. Medicina (B Aires) 2005, 65(4):289-294.
• [23]White RH: The epidemiology of venous thromboembolism. Circulation 2003, 107(23 Suppl 1):I4-I8.
• [24]Flinterman LE, van Hylckama VA, Cannegieter SC, Rosendaal FR: Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors. PLoS Med 2012, 9(1):e1001155.
• [25]Vázquez F, Posadas-Martínez M, Vicens J, González Bernaldo de Quirós F, Giunta D: Incidence rate of symptomatic venous thromboembolic disease in patients from a medical care program in Buenos Aires, Argentina: a prospective cohort. Thromb J 2013, 11(1):16. BioMed Central Full Text
• [26]Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, Turpie AG, Bormanis J, Weitz J, Chamberlain M, Bowie D, Barnes D, Hirsh J: Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000, 83(3):416-420.
• [27]Posadas-Martinez ML, Vazquez FJ, Giunta DH, Waisman GD, de Quiros FG, Gandara E: Performance of the Wells score in patients with suspected pulmonary embolism during hospitalization: a delayed-type cross sectional study in a community hospital. Thromb Res 2014, 133(2):177-181.
• [28]Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C: Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ 2011, 342:d3036.
• [29]Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P, WARFASA investigators: Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012, 366(21):1959-1967.
• [30]Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, Poli D, Lim W: Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 2008, 149(7):481-490. W494
• [31]Marcucci M, Iorio A, Douketis J: Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. Curr Treat Options Cardiovasc Med 2013, 15(2):224-239.
• [32]Schulman S, Kearon C: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005, 3(4):692-694.
• [33]Heit JA: Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost: JTH 2005, 3(8):1611-1617.
• [34]Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G, Lite trial investigators: Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006, 119(12):1062-1072.
• [35]Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd: Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999, 159(5):445-453.
• [36]Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE: A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991, 151(5):933-938.
• [37]van Beek EJ, Kuijer PM, Buller HR, Brandjes DP, Bossuyt PM, ten Cate JW: The clinical course of patients with suspected pulmonary embolism. Arch Intern Med 1997, 157(22):2593-2598.
• [38]Bertoletti L, Le Gal G, Aujesky D, Roy PM, Sanchez O, Verschuren F, Bounameaux H, Perrier A, Righini M: Prognostic value of the Geneva prediction rule in patients in whom pulmonary embolism is ruled out. J Intern Med 2011, 269(4):433-440.
• [39]Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998, 338(17):1169-1173.
• [40]Fennerty T: Screening for cancer in venous thromboembolic disease. BMJ 2001, 323(7315):704-705.
• [41]Sorensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P: Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007, 370(9601):1773-1779.
• [42]Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992, 327(16):1128-1133.
• [43]Maestre A, Trujillo-Santos J, Visona A, Lobo JL, Grau E, Maly R, Duce R, Monreal M, Investigators R: D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer. Thromb Res 2014, 133(3):384-389.